Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Bristol-Myers Squibb Co, widely known BMS- a renowned pharmaceutical company in the United States declared on September 6, 2017, that they have succeeded in testing the combination therapy and treatment to boost overall survival in patients suffering from kidney cancer. This success has helped the company to end its trial before the planned schedule, despite previous reports generated had mixed results considering other chief goals.

The company mentioned in a statement that an amalgamation of Yervoy and Opdivo, its two key medications, showed higher total survival rates compared to a standard care medication that was used to treat formerly untreated patients suffering from metastatic or advanced renal cell carcinoma. In August 2017, Bristol- Myers quoted that the amalgamated treatment failed in improving progression-free cancer survival in most of the patients. However, it was successful in decreasing the size of the cancer tumor in many patients.

Research analyst from Leerink, Seamus Fernandez had written in a client note that, “we are of a belief that the total survival advantage is most likely to confirm the durability of the indication noticed on progression-free survival, thus resulting in an extremely high likelihood of medication approval.” As per the information given by Cowen and Co, the trials to gauge the complete survival rates are expected to be executed during the second half of 2019. Bristol-Myers added that the trail was ended before time after the results of a planned interim analysis were successful. This also helped the company shares to went up by 4.2 percent and reach a 52-week high amounting to US$ 62.415 this time.
The shares of Exelixis Inc- a rival pharmaceutical company which is in process of manufacturing a competitive treatment for kidney cancer, dropped down by 10 percent. In addition, trial results of Bristol-Myers increased hopes and expectations for lung cancer therapy from AstraZeneca Plc that failed to deliver progression-free survival in July.

You may be interested

2018 – 2023 Industrial Jet Compressor Market | Manufacturing Technology, Market Status And Professional Outlook
Business
Business

2018 – 2023 Industrial Jet Compressor Market | Manufacturing Technology, Market Status And Professional Outlook

Albert R - December 12, 2018

Industrial Jet Compressor Market is anticipated to have maximum growth during years 2018 to 2023 according to the latest research made by WMR. This Industrial Jet Compressor…

Semi-Metallic Gasket Sheet Market 2018 -2023 Market Demand, Key Players And Opportunities
Business
Business

Semi-Metallic Gasket Sheet Market 2018 -2023 Market Demand, Key Players And Opportunities

Albert R - December 12, 2018

Semi-Metallic Gasket Sheet Market is anticipated to have maximum growth during years 2018 to 2023 according to the latest research made by WMR. This Semi-Metallic Gasket Sheet…

Business

Metallic Flange Gasket Sheet Market Product Type, Application And Key Objective, Period 2018 – 2023

Albert R - December 12, 2018

Metallic Flange Gasket Sheet Market is anticipated to have maximum growth during years 2018 to 2023 according to the latest research made by WMR. This Metallic Flange…

Most from this category